Alan Leshner, CEO of the American Association for the Advancement of Science, caused a stir at February’s EU ministerial conference in Copenhagen, with a hard-hitting speech on the state of US science. America's scientific eminence, 'is at risk' he said.
A private equity firm is to raise the largest specialist fund in the world dedicated to commercialising university R&D. The money will be invested in partnership with three of the UK’s leading research universities
The US patent office has released studies on international patenting and prior user defence, with other reports looking at the US patents scene to follow
Hard-pressed healthcare systems can no longer pay premium prices for new drugs. The consequence will be less innovation in Europe says Andrew Witty, CEO of GlaxoSmithKline.
25 countries have agreed to back a single European research plan in neurodegenerative diseases. This is a defining moment for coordinated research says the Commissioner
The European Commission proposes to unite national funding agencies in ‘pacts’ to complete the European Research Area (ERA) by 2014 deadline - without further legislation
Only world-class science will deliver the innovation and growth Europe so desperately needs. US experience can help EU policy makers understand how to enhance R&D productivity and encourage excellence, says Paula Stephan
The $1,000 genome has arrived, providing the spur for personalised healthcare to move from theory to practice. Some existing examples of best practice and roadmaps for the future are pointing the way
A new study finds that investment in computer, communications and diagnostics technologies could drastically cut the long-term care costs for breast cancer and cardiovascular disease, through better use of patient screening and adherence to treatment.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.